Skip to main content
SpringerLink
Log in

Surgery for Adrenocortical Cancer: Evidence-Based Recommendations

  • Chapter
  • First Online:
Evidence-Based Endocrine Surgery

Abstract

Adrenocortical carcinoma (ACC) is an exceedingly rare tumour associated with poor survival for which radical surgical excision remains the only potentially curative treatment. This chapter is based on data collected by the author during publication of a systematic review of this topic published in the British Journal of Surgery [1] and during work as a senior author of guidelines for perioperative care of ACC patients published through a collaboration between the European Society of Endocrine Surgeons (ESES) and the European Network for the Study of Adrenal Tumours (ENSAT) [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mihai R. Diagnosis, treatment and outcome of adrenocortical cancer. Br J Surg. 2015;102(4):291–306.

    Article  CAS  Google Scholar 

  2. Gaujoux S, et al. European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg. 2017;104(4):358–76.

    Article  CAS  Google Scholar 

  3. Kutikov A, et al. Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database. J Urol. 2011;186(3):805–10.

    Article  Google Scholar 

  4. Kerkhofs TM, et al. Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013;169(1):83–9.

    Article  CAS  Google Scholar 

  5. Fassnacht M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115(2):243–50.

    Article  Google Scholar 

  6. Arlt W, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12):3775–84.

    Article  CAS  Google Scholar 

  7. Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol. 2011;60(5):1055–65.

    Article  Google Scholar 

  8. Zhang HM, et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clin Radiol. 2012;67(1):38–46.

    Article  CAS  Google Scholar 

  9. Sturgeon C, et al. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg. 2006;202(3):423–30.

    Article  Google Scholar 

  10. Abdel-Aziz TE, et al. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm. World J Surg. 2015;39(5):1268–73.

    Article  Google Scholar 

  11. Petersenn S, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol. 2015;172(4):415–22.

    Article  CAS  Google Scholar 

  12. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer. 2007;14(1):13–28.

    Article  CAS  Google Scholar 

  13. Ilias I, et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007;14(3):587–99.

    Article  Google Scholar 

  14. Harrison B. The indeterminate adrenal mass. Langenbeck’s Arch Surg. 2012;397(2):147–54.

    Article  Google Scholar 

  15. Gust L, et al. Preoperative 18F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors. World J Surg. 2012;36(6):1406–10.

    Article  Google Scholar 

  16. Nunes ML, et al. 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg. 2010;34(7):1506–10.

    Article  Google Scholar 

  17. Watanabe H, et al. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT. Ann Nucl Med. 2013;27(7):648–53.

    Article  CAS  Google Scholar 

  18. Tessonnier L, et al. (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value. World J Surg. 2013;37(1):107–12.

    Article  CAS  Google Scholar 

  19. Kreissl MC, et al. [(1)(2)(3)I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(7):2755–64.

    Article  CAS  Google Scholar 

  20. Lughezzani G, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46(4):713–9.

    Article  Google Scholar 

  21. Waldmann J, et al. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbeck's Arch Surg. 2012;397(2):209–16.

    Article  Google Scholar 

  22. Herrmann LJ, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97(3):E476–85.

    Article  CAS  Google Scholar 

  23. Raymond VM, et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):E119–25.

    Article  CAS  Google Scholar 

  24. Tran TB, et al. Surgical management of advanced adrenocortical carcinoma: a 21-year population-based analysis. Am Surg. 2013;79(10):1115–8.

    PubMed  Google Scholar 

  25. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012;152(1):123–32.

    Article  Google Scholar 

  26. Lim JH, Auh YH. Anatomic relation between the bare area of the liver and the right perirenal space. AJR Am J Roentgenol. 1994;162(3):733–4.

    Article  CAS  Google Scholar 

  27. Lim JH, Kim B, Auh YH. Continuation of gas from the right perirenal space into the bare area of the liver. J Comput Assist Tomogr. 1997;21(4):667–70.

    Article  CAS  Google Scholar 

  28. Icard P, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25(7):891–7.

    Article  CAS  Google Scholar 

  29. Gaujoux S, et al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol. 2012;19(8):2643–51.

    Article  Google Scholar 

  30. Bellantone R, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122(6):1212–8.

    Article  CAS  Google Scholar 

  31. Fiori C, Daffara F, Defrancia S. Does nephrectomy during adrenalectomy for adrenal cancer improve oncological results? Eur Urol. 2012;11(1):e1105.

    Article  Google Scholar 

  32. Bilimoria KY, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113(11):3130–6.

    Article  Google Scholar 

  33. Fassnacht M, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(11):4501–4.

    Article  CAS  Google Scholar 

  34. Erdogan I, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):181–91.

    Article  CAS  Google Scholar 

  35. Kendrick ML, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001;136(5):543–9.

    Article  CAS  Google Scholar 

  36. Libe R, et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26(10):2119–25.

    Article  CAS  Google Scholar 

  37. Nilubol N, Patel D, Kebebew E. Does lymphadenectomy improve survival in patients with adrenocortical carcinoma? A population-based study. World J Surg. 2016;40(3):697–705.

    Article  Google Scholar 

  38. Saade N, Sadler C, Goldfarb M. Impact of regional lymph node dissection on disease specific survival in adrenal cortical carcinoma. Horm Metab Res. 2015;47(11):820–5.

    Article  CAS  Google Scholar 

  39. Soreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970–1984. World J Surg. 1992;16(4):663–7; discussion 668

    Article  CAS  Google Scholar 

  40. King DR, Lack EE. Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer. 1979;44(1):239–44.

    Article  CAS  Google Scholar 

  41. Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg. 1999;134(2):181–5.

    Article  CAS  Google Scholar 

  42. Reibetanz J, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255(2):363–9.

    Article  Google Scholar 

  43. Chiche L, et al. Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery. 2006;139(1):15–27.

    Article  Google Scholar 

  44. Turbendian HK, et al. Adrenocortical carcinoma: the influence of large vessel extension. Surgery. 2010;148(6):1057–64; discussion 1064.

    Article  Google Scholar 

  45. Mihai R, et al. Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava--a European Society of Endocrine Surgeons (ESES) survey. Langenbeck’s Arch Surg. 2012;397(2):225–31.

    Article  Google Scholar 

  46. Bednarski BK, et al. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World J Surg. 2014;38(6):1318–27.

    Article  Google Scholar 

  47. Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.

    Article  CAS  Google Scholar 

  48. Dy BM, et al. Operative intervention for recurrent adrenocortical cancer. Surgery. 2013;154(6):1292–9; discussion 1299

    Article  Google Scholar 

  49. Jurowich C, et al. Is there a role for laparoscopic adrenalectomy in patients with suspected adrenocortical carcinoma? A critical appraisal of the literature. Horm Metab Res. 2013;45(2):130–6.

    Article  CAS  Google Scholar 

  50. Carnaille B. Adrenocortical carcinoma: which surgical approach? Langenbeck's Arch Surg. 2012;397(2):195–9.

    Article  Google Scholar 

  51. Else T, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282–326.

    Article  CAS  Google Scholar 

  52. Di Carlo I, et al. Liver resection for hepatic metastases from adrenocortical carcinoma. HPB (Oxford). 2006;8(2):106–9.

    Article  Google Scholar 

  53. Ripley RT, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011;18(7):1972–9.

    Article  Google Scholar 

  54. op den Winkel J, et al. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. Ann Thorac Surg. 2011;92(6):1965–70.

    Article  Google Scholar 

  55. Kemp CD, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg. 2011;92(4):1195–200.

    Article  Google Scholar 

  56. Dy BM, et al. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015;22(1):146–51.

    Article  Google Scholar 

  57. Porpiglia F, et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer. 2011;2(6):372–7.

    Article  Google Scholar 

  58. Aspinall SR, et al. How is adrenocortical cancer being managed in the UK? Ann R Coll Surg Engl. 2009;91(6):489–93.

    Article  Google Scholar 

  59. Grubbs EG, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17(1):263–70.

    Article  Google Scholar 

  60. Hermsen IG, et al. Surgery in adrenocortical carcinoma: importance of national cooperation and centralized surgery. Surgery. 2012;152(1):50–6.

    Article  Google Scholar 

  61. Ip JC, et al. Improving outcomes in adrenocortical cancer: an Australian perspective. Ann Surg Oncol. 2015;22(7):2309–16.

    Article  Google Scholar 

  62. Bergamini C, et al. Complications in laparoscopic adrenalectomy: the value of experience. Surg Endosc. 2011;25(12):3845–51.

    Article  Google Scholar 

  63. Park HS, Roman SA, Sosa JA. Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Arch Surg. 2009;144(11):1060–7.

    Article  Google Scholar 

  64. Simhan J, et al. Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol. 2012;188(2):377–82.

    Article  Google Scholar 

  65. Gallagher SF, et al. Trends in adrenalectomy rates, indications, and physician volume: a statewide analysis of 1816 adrenalectomies. Surgery. 2007;142(6):1011–21. discussion 1011-21

    Article  Google Scholar 

  66. Saunders BD, et al. Trends in utilization of adrenalectomy in the United States: have indications changed? World J Surg. 2004;28(11):1169–75.

    Article  Google Scholar 

  67. Lombardi CP, et al. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbeck’s Arch Surg. 2012;397(2):201–7.

    Article  Google Scholar 

  68. Fassnacht M, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95(11):4925–32.

    Article  CAS  Google Scholar 

  69. Gratian L, et al. Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. In: Ann Surg Oncol, vol. 21; 2014. p. 3509.

    Google Scholar 

  70. Greco F, et al. Laparoscopic adrenalectomy in urological centres—the experience of the German Laparoscopic Working Group. BJU Int. 2011;108(10):1646–51.

    Article  Google Scholar 

  71. Margonis GA, et al. Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg. 2016;211(6):1106–13.

    Article  Google Scholar 

  72. Margonis GA, et al. Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol. 2016;23(1):134–41.

    Article  Google Scholar 

  73. Papotti M, et al. Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors. Endocr Pathol. 2014;25(1):35–48.

    Article  CAS  Google Scholar 

  74. Beuschlein F, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100(3):841–9.

    Article  CAS  Google Scholar 

  75. Zini L, et al. External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU Int. 2009;104(11):1661–7.

    Article  Google Scholar 

  76. Freire DS, et al. Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence. Clin Endocrinol. 2013;79(4):468–75.

    Article  Google Scholar 

  77. de Krijger RE, Bertherat J. 5th international ACC symposium: classification of adrenocortical cancers from pathology to integrated genomics: real advances or lost in translation? Horm Cancer. 2016;7(1):3–8.

    Article  Google Scholar 

Download references

Acknowledgement

Disclosure: The author declares no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Endocrine Surgery, Churchill Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

    Radu Mihai

Authors
  1. Radu Mihai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Radu Mihai .

Editor information

Editors and Affiliations

  1. Division of Endocrine Surgery, National University Hospital, Singapore, Singapore

    Rajeev Parameswaran

  2. Department of Endocrine Surgery, SGPGI Hospital, Lucknow, India

    Amit Agarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media Singapore

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mihai, R. (2018). Surgery for Adrenocortical Cancer: Evidence-Based Recommendations. In: Parameswaran, R., Agarwal, A. (eds) Evidence-Based Endocrine Surgery. Springer, Singapore. https://doi.org/10.1007/978-981-10-1124-5_29

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1124-5_29

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1123-8

  • Online ISBN: 978-981-10-1124-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation